Klaus A. Dugi

5.6k citations

72 papers · 4.4k indexed · h-index 39

Endocrinology, Diabetes and Metabolism top 0.2%
Surgery top 2%
Molecular Biology top 5%
Oncology top 5%
Cardiology and Cardiovascular Medicine top 2%

Co-authors: Hans J. Woerle Silvia Santamarina-Fojo Arne Ring Maximilian von Eynatten Eva U. Graefe-Mody Peter P. Nawroth Julio Rosenstock H. Bryan Brewer
Topics: Diabetes Treatment and Management (25 papers)Pancreatic function and diabetes (19 papers)Lipid metabolism and disorders (13 papers)
Cited by: Endocrinology, Diabetes and Metabolism Surgery Cardiology and Cardiovascular Medicine
Journals: The Lancet Journal of Biological Chemistry Circulation
Partner nations: Germany United States United Kingdom

In The Last Decade

Klaus A. Dugi

71 papers receiving 4.2k citations

Peers

Countries citing papers authored by Klaus A. Dugi

Since Specialization

Citations

This map shows the geographic impact of Klaus A. Dugi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus A. Dugi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus A. Dugi more than expected).

Fields of papers citing papers by Klaus A. Dugi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus A. Dugi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus A. Dugi. The network helps show where Klaus A. Dugi may publish in the future.

Co-authorship network of co-authors of Klaus A. Dugi

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus A. Dugi. A scholar is included among the top collaborators of Klaus A. Dugi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus A. Dugi. Klaus A. Dugi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer 2020 ·JACC CardioOncology ·Chiara Melloni,Susan F. Slovin,Allan Blemings,Shaun G. Goodman,Christopher P. Evans,Jan Nilsson,Deepak L. Bhatt,(unknown),Tine Kold Olesen,Klaus A. Dugi,Noel W. Clarke,Celestia S. Higano,Matthew T. Roe	39
2	The Boehringer Ingelheim employee study (Part 2): 10-year cardiovascular diseases risk estimation 2016 ·Occupational Medicine ·Kerstin Kempf,Stéphan Martin,(unknown),Klaus A. Dugi,Burkhard Haastert,Michael F. Schneider	3
3	Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects 2013 ·Clinical Pharmacology in Drug Development ·Leo Seman,Sreeraj Macha,Gerhard Nehmiz,(unknown),(unknown),Sabine Pinnetti,Hans J. Woerle,Klaus A. Dugi	111
4	The Epidemiological Boehringer Ingelheim Employee Study—Part I: Impact of Overweight and Obesity on Cardiometabolic Risk 2013 ·Journal of Obesity ·Kerstin Kempf,Stéphan Martin,(unknown),Klaus A. Dugi,(unknown),Burkhard Haastert,Michael F. Schneider	12
5	Die Gutenberg Gesundheitsstudie 2012 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·Philipp S. Wild,Tanja Zeller,Manfred E. Beutel,Maria Blettner,Klaus A. Dugi,Karl J. Lackner,Norbert Pfeiffer,Thomas Münzel,Stefan Blankenberg	191
6	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects 2012 ·Drug Metabolism and Pharmacokinetics ·Akiko Sarashina,Kazuki Koiwai,Leo Seman,Norio Yamamura,Atsushi Taniguchi,T Negishi,Shogo Sesoko,Hans J. Woerle,Klaus A. Dugi	73
7	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial 2012 ·The Lancet ·Baptist Gallwitz,Julio Rosenstock,T. Rauch,Sudipta Bhattacharya,Sanjay Patel,Maximilian von Eynatten,Klaus A. Dugi,Hans‐Juergen Woerle	277
8	Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients 2011 ·Clinical Therapeutics ·Yoshiharu Horie,Shigeto Kanada,Hirotaka Watada,Akiko Sarashina,Atsushi Taniguchi,Naoyuki Hayashi,Eva U. Graefe-Mody,Hans‐Juergen Woerle,Klaus A. Dugi	42
9	Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study 2011 ·Diabetes Obesity and Metabolism ·Ramón Gomis,(unknown),Russell Jones,H.J. Woerle,Klaus A. Dugi	161
10	Effect of linagliptin monotherapy on glycaemic control and markers of β ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial 2010 ·Diabetes Obesity and Metabolism ·Stefano Del Prato,Anthony Barnett,Holger Huisman,Dietmar Neubacher,Hans J. Woerle,Klaus A. Dugi	259
11	Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin 2010 ·International Journal of Clinical Pharmacology and Therapeutics ·Ulrike Graefe‐Mody,Steven Huettner,(unknown),Arne Ring,Klaus A. Dugi	35
12	Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study 2010 ·Diabetes Obesity and Metabolism ·Marja‐Riitta Taskinen,Julio Rosenstock,Ilkka Tamminen,(unknown),S. Patel,Klaus A. Dugi,Hans J. Woerle	261
13	Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease 2007 ·Diabetologia ·Maximilian von Eynatten,Philipp M. Lepper,D. Liu,Katharina Lang,Marcus Baumann,Peter P. Nawroth,Angelika Bierhaus,Klaus A. Dugi,Uwe Heemann,Bruno Allolio,Per M. Humpert	146
14	Effect of thiol antioxidant on body fat and insulin reactivity 2004 ·Journal of Molecular Medicine ·Wulf Hildebrandt,A. Hamann,Holger Krakowski‐Roosen,Ralf Kinscherf,Klaus A. Dugi,Roland Sauer,(unknown),(unknown),(unknown),(unknown),Lutz Edler,Peter Nawroth,(unknown)	41
15	Siblings with hepatosplenomegaly and lipoprotein lipase deficiency 2002 ·The Lancet ·Jochen G. Schneider,(unknown),B. Lettgen,Tanja Keiper,Peter P. Nawroth,Klaus A. Dugi	3
16	Activity and concentration of lipoprotein lipase in post-heparin plasma and the extent of coronary artery disease 2002 ·Atherosclerosis ·Klaus A. Dugi,(unknown),(unknown),(unknown),W. Fiehn,Joerg Kreuzer	11
17	Lipoproteins and the Endothelium: Insights from Clinical Research 2000 ·Seminars in Thrombosis and Hemostasis ·Klaus A. Dugi,Daniel J. Rader	4
18	Polymorphisms of apolipoproteins A-IV and E in a Turkish population living in Germany 1996 ·Human Genetics ·Ernst Malle,Karl Pfeiffer,Klaus A. Dugi,(unknown),Martin Glaum,(unknown),H. U. Kloer,Armin Steinmetz	12
19	A novel A–>G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. 1996 ·Journal of Lipid Research ·Korbinian Brand,Klaus A. Dugi,JD Brunzell,David Nevin,Silvia Santamarina-Fojo	45
20	WELCHE ROLLE SPIELT DAS RENIN-ANGIOTENSIN-ALDOSTERON-SYSTEM (RAAS) IN DER PATHOGENESE DER HYPERTONIE BEIM OBSTRUKTIVEN SCHLAFAPNOE-SYNDROM (OSAS)? 1991 ·K. Ehlenz,H. Schneider,Klaus A. Dugi,J. H. Peter,P. von Wichert,H. Kaffarnik	2

About Klaus A. Dugi

Klaus A. Dugi is a scholar working on Endocrinology, Diabetes and Metabolism, Biochemistry and Cardiology and Cardiovascular Medicine, having authored 72 papers that have together received 4.4k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (25 papers), Pancreatic function and diabetes (19 papers) and Lipid metabolism and disorders (13 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.9k citations), Surgery (1.6k citations) and Cardiology and Cardiovascular Medicine (741 citations). Klaus A. Dugi has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Hans J. Woerle, Silvia Santamarina-Fojo, Arne Ring, Maximilian von Eynatten, Eva U. Graefe-Mody, Peter P. Nawroth, Julio Rosenstock, H. Bryan Brewer, Hans‐Juergen Woerle and Jochen G. Schneider. Their work appears in journals such as The Lancet, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact